Vicore Pharma Holding AB (OSTO:VICO BTA) 3-Year EBITDA Growth Rate : 33.20% (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB 3-Year EBITDA Growth Rate?

Vicore Pharma Holding AB's EBITDA per Share for the three months ended in Mar. 2025 was kr-7.49.

During the past 3 years, the average EBITDA Per Share Growth Rate was 33.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vicore Pharma Holding AB was 33.20% per year. The lowest was -65.90% per year. And the median was -32.85% per year.

Competitive Comparison of Vicore Pharma Holding AB's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Vicore Pharma Holding AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Vicore Pharma Holding AB 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Vicore Pharma Holding AB (OSTO:VICO BTA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Vicore Pharma Holding AB 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

VICO:Sweden

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines